Seoul scientists uncover osteoporosis breakthrough with bone cell reactivation

A breakthrough in osteoporosis research has emerged from Seoul National University. Scientists there have uncovered a molecular pathway that could transform how the condition is treated. Their findings shed new light on how bone cells behave—and how they might be reactivated to combat bone loss. Osteoporosis weakens bones by disrupting the balance between cells that break down old bone (osteoclasts) and those that build new bone (osteoblasts). Over time, this imbalance leads to fragile bones and a higher risk of fractures. While anti-sclerostin treatments have shown potential in waking up dormant bone-lining cells, the exact triggers for this reactivation remained unclear.

The research team used advanced transcriptomic mapping to study osteoblast behaviour in fine detail. They identified three distinct states of these cells: actively building bone, lying dormant, or reactivating after treatment. A key discovery was the role of TGF-β, a signalling molecule that keeps osteoblasts inactive. Blocking this pathway, however, encouraged dormant cells to spring back into action. Experiments on mice with induced bone loss confirmed the findings. When TGF-β and sclerostin were both inhibited, bone volume, thickness, and formation rates improved dramatically. At the same time, markers of bone breakdown decreased. The combined treatment also boosted the number and thickness of osteoblast lineage cells more effectively than targeting either pathway alone.

The study reveals how TGF-β controls osteoblast dormancy and how its inhibition could enhance existing therapies. By pairing TGF-β blockade with anti-sclerostin drugs, bone regeneration may be significantly improved. These insights open new avenues for developing more effective osteoporosis treatments in the future.